Orasure Technologies (EP3) Stock Price & Analysis
EP3 Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 224.13M
- Enterprise Value
- CHF 169.65M
- Total Cash (Recent Filing)
- CHF 160.58M
- Total Debt (Recent Filing)
- CHF 12.09M
- Price to Earnings (P/E)
- ―
- Beta
- 0.98
- Next Earnings
- Nov 09, 2026 (Est.)
- EPS Estimate
- -0.17
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Liquidity
The combination of $161 million in cash and zero debt gives OraSure meaningful financial flexibility over the next several quarters. This liquidity can fund product launches, regulatory work, and operating needs without immediate reliance on borrowing, while reducing balance-sheet stress during the recovery.
Regulatory Product Progress
Clearance of Colli-Pee for eight STI indications and authorization for Ebola 2.0 expand the company’s commercially usable product portfolio. These milestones support future revenue opportunities, strengthen OraSure’s diagnostic capabilities, and provide launch platforms beyond its existing products.
Sequential Recovery And Margin Improvement
Sequential growth across the business, together with higher gross margin, indicates that recent operating actions are beginning to improve execution. Lower scrap, operational efficiencies, and recovery in Diagnostics and SMS could support a more sustainable earnings trajectory if the trend continues.
Bears Say
Severe Revenue And Profitability Decline
The sharp TTM revenue contraction and deeply negative operating and net margins show that OraSure’s current expense base is not aligned with its reduced sales level. This weak earnings profile limits internal funding capacity and makes a durable recovery dependent on renewed demand and cost improvement.
Persistent Cash Burn
Sustained operating and free-cash-flow losses are a material fundamental weakness because they consume liquidity while the company remains unprofitable. Although management targets operating cash-flow breakeven entering 2027, continued burn before then could constrain investment flexibility and increase execution pressure.
IntelliQ Regulatory Setback
The IntelliQ withdrawal removes an expected near-term product catalyst and leaves the timing of resubmission and clearance uncertain. Delayed commercialization can defer potential revenue, extend development spending, and increase dependence on Colli-Pee, Ebola 2.0, and existing products to drive recovery.
Orasure Technologies News
EP3 FAQ
What is Orasure Technologies’s market cap?
When is Orasure Technologies’s upcoming earnings report date?
How were Orasure Technologies’s earnings last quarter?
Is Orasure Technologies overvalued?
Does Orasure Technologies pay dividends?
What is Orasure Technologies’s EPS estimate?
How many shares outstanding does Orasure Technologies have?
What happened to Orasure Technologies’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Orasure Technologies?
What is the TipRanks Smart Score and how is it calculated?
Orasure Technologies Stock Smart Score
Company Description
Orasure Technologies
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Carrie Eglinton Manner
- Employees
- 500
- Website
- www.orasure.com
- Address
- 220 East First Street, Bethlehem, PA, 18015, US
Orasure Technologies (EP3) Earnings & Revenues
EP3 Earnings Call
Earnings Call SentimentPositive
The call presents a cautiously positive picture: the company delivered sequential revenue growth (9.7%), segment recoveries (Diagnostics +14.7% and SMS +9.0% sequentially), margin expansion (+120 bps GAAP gross margin) and achieved important regulatory milestones (Colli‑Pee FDA clearance and Ebola 2.0 EUA). The primary setback is the withdrawal and delay of the IntelliQ CT/NG FDA submission, alongside a non‑GAAP operating loss ($14.7M) and negative operating cash flow (‑$9.9M) this quarter. Strong cash ($161M), zero debt, insourcing and cost discipline, and clear launch plans temper the impact of the IntelliQ delay and one‑time G&A items; management reiterates revenue growth for 2026 and expects operating cash flow breakeven entering 2027.
View all CH:EP3 earnings summaries